ARTICLE | Clinical News

Cepheid gains on TB test data

September 3, 2010 12:06 AM UTC

Cepheid Inc. (NASDAQ:CPHD) gained $1.50 (10%) to $17.27 on Thursday after reporting that its Xpert MTB/RIF assay had 98.2% sensitivity for patients with smear-positive, culture-positive tuberculosis (TB) and 99.2% specificity for patients without TB in a pivotal trial. The test also had 97.6% sensitivity for patients with rifampin-resistant bacteria and 98.1% sensitivity for patients with rifampin-sensitive bacteria. The international trial enrolled 1,730 patients with suspected drug-sensitive or multidrug-resistant pulmonary TB. Data were published in the New England Journal of Medicine. ...